Viral Pneumonia Clinical Trial
Official title:
Use of High Flow Nasal Cannula Oxygen During Acute Hypoxemic Respiratory Failure Related to Covid-19 and Interest of the Respiratory-oxygenation Index (ROX Index): an Observational Study
Nasal High Flow oxygen therapy (NHF) is commonly used as first line ventilatory support in patients with acute hypoxemic respiratory failure (AHRF). It's use has been initially limited in Covid-19 patients presenting with AHRF. The aim of the study is to describe the use of NHF in Covid-19-related AHRF and report the changes in the respiratory-oxygenation index (termed ROX index) over time in these patients.
Nasal High Flow oxygen therapy (NHF) is one of the newer methods of oxygenation commonly used
in critical care during acute hypoxemic respiratory failure (AHRF). For various reasons (fear
of a putative risk of viral dispersion; initial recommendations for rapid intubation due to
the rapid deterioration of patients), NHF seems to have been seldomly used during the current
Covid-19 epidemic in France. However, the World Health Organization, and other scientific
societies list NHF among the possible options for ventilatory support.
One of the risks however, identified with NHF is to delay an intubation that would have
become necessary. This delay seems to be associated with a poorer prognosis for patients.
The respiratory-oxygenation index (termed ROX index) (defined as the ratio of pulse oximetry
(SpO2) over inspired fraction in oxygen (FiO2) over respiratory rate (RR); SpO2/FiO2/RR) is
used - along with other criteria - to assist the clinician in deciding whether or not to
intubate patients on NHF for AHRF. In investigators'ICU, NHF is used in patients admitted for
AHRFrelated to Covid-19 and the ROX index is measured and monitoring in investigators'
patients. Investigators' initial experience - consistent with feedback from other ICUs -
suggests that the respiratory rate of patients with Covid-19-related AHRF is sometimes lower
than would be expected given the depth of the hypoxemia. In this case, the ROX index
thresholds previously identified for predicting the success or failure of NHF could be
different in the case of Covid-19-associated AHRF. The purpose of this work is to describe
the use of NHF in Covid-19 patients with AHRF and the evolution of the ROX score over time in
patients initially treated with NHF.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05286255 -
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
|
Phase 1 | |
Recruiting |
NCT04952337 -
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
|
||
Completed |
NCT04606407 -
Inhaled NO for the Treatment of Viral Pneumonia in Adults
|
N/A | |
Not yet recruiting |
NCT05612893 -
Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
|
||
Not yet recruiting |
NCT04397497 -
Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)
|
Phase 2 | |
Terminated |
NCT04345289 -
Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
|
Phase 3 | |
Enrolling by invitation |
NCT04326036 -
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
|
Early Phase 1 | |
Withdrawn |
NCT00645619 -
Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
|
||
Not yet recruiting |
NCT04876573 -
Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
|
Phase 2 | |
Unknown status |
NCT01612572 -
A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals
|
N/A | |
Completed |
NCT02152358 -
PTH - Preemptive Treatment for Herpesviridae
|
Phase 4 | |
Completed |
NCT04644302 -
Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis
|
||
Recruiting |
NCT05531149 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
|
Phase 3 | |
Not yet recruiting |
NCT04955223 -
Yinhu Qingwen Granule in the Treatment of Viral Pneumonia
|
Early Phase 1 | |
Completed |
NCT01868113 -
Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial
|
Phase 3 | |
Recruiting |
NCT04380376 -
Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia
|
Phase 2 | |
Completed |
NCT05386459 -
Study of the Use of the Drug Ingaron in Patients With COVID-19
|
||
Not yet recruiting |
NCT06349707 -
Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic
|
||
Completed |
NCT04394026 -
Imaging Feature of SARS-CoV2 Infection
|
||
Not yet recruiting |
NCT04820751 -
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
|
Phase 3 |